Product Description
For Relapsing-remitting Multiple Sclerosis (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02744222)
Mechanisms of Action: Unknown
Novel Mechanism: Yes
Modality: Large Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Biocad
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Multiple Sclerosis, Relapsing-Remitting
Phase 1: Healthy Volunteers